search
Back to results

Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients

Primary Purpose

OCD

Status
Recruiting
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
N-acetylcysteine tablet 600mg
Placebo tablet 600mg
Sponsored by
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for OCD focused on measuring N-acetylcysteine, OCD, MRS, Glutamate

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed OCD patients diagnosed by Psychiatric Consultant of the Department of Psychiatry according to DSM-5 criteria (Appendix VI).
  • Moderate to severe OCD patients having AY-BOCS score > 16
  • Age: 18 years or above
  • Sex: Both male and female

Exclusion Criteria:

Patients receiving antidepressant within last two months.

  • Patients having any history of psychiatric and medical conditions will be excluded from the study.
  • Patients having suicidal thoughts.
  • Pregnancy and lactation.
  • Patients who are receiving psychotherapy.

Sites / Locations

  • BSMMURecruiting
  • Sadia Binte Anwar SoniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Experimental

Control

Arm Description

This arm includes 30 OCD patients receiving SSRIs

This arm includes 30 OCD patients receiving SSRIs

Outcomes

Primary Outcome Measures

OCD severity score assessment
Assess the severity score of OCD symptoms by YBOCS-10 at baseline, after 4 weeks, and after10 weeks. And compare the score between two groups. YBOCS-10 range from 0-40 with the following scores: 0-14 Non significant to mild, 15-23 Mild to moderate, 23-29 Moderate to severe, 30-40 Severe to disabling.

Secondary Outcome Measures

Neurochemical assessment
To estimate the brain glutamate level by Magnetic Resonance Spectroscopy (MRS) at baseline and after 10 weeks supplementation of n-acetylcysteine and SSRI. To compare the brain glutamate level by Magnetic Resonance Spectroscopy (MRS) at baseline and after 10 weeks supplementation of n-acetylcysteine and SSRI.

Full Information

First Posted
May 23, 2021
Last Updated
November 14, 2021
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
search

1. Study Identification

Unique Protocol Identification Number
NCT04904952
Brief Title
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
Official Title
Effect of N-acetylcysteine as Add on Therapy With Selective Serotonin Reuptake Inhibitors in Moderate to Severe Obsessive Compulsive Disorder Patients
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 13, 2020 (Actual)
Primary Completion Date
January 10, 2022 (Anticipated)
Study Completion Date
January 10, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Title: Effect of n-acetylcysteine as add-on therapy with Selective Serotonin Reuptake Inhibitors in moderate to severe Obsessive Compulsive Disorder patients. Purpose of the study: To assess the effects of the addition of n-acetylcysteine with SSRIs on the severity of symptoms in obsessive-compulsive disorder patients.
Detailed Description
Obsessive-compulsive disorder (OCD) is the fourth most common mental disorder in Bangladesh and around the world. Selective serotonin reuptake inhibitors (SSRIs) are commonly administered drugs for treating children and adolescents with OCD. The treatment of this condition has remained unsatisfactory, only 40-60% of patients with OCD respond to SSRIs, and about 40 to 60% of patients with OCD do not completely respond to this drug. Researchers throughout the world are involved to obtain new pharmacotherapy for the treatment of OCD. A good number of evidences have proved that glutamate plays a significant role in the pathophysiology of OCD.N-acetylcysteine (NAC) is an amino acid derivative, is a health supplement, and has neuroprotective effects that target the glutamatergic system. Some recent trials attempted to assess the effect of n-acetylcysteine as an add-on therapy with SSRIs to improve symptoms in OCD patients. Aim: This proposed study is therefore an effort whether there is any role of n-acetylcysteine adjuncts with SSRI produce better improvement than SSRI alone in OCD patients. Method: This study will be a randomized, double-blind, placebo-controlled multicenter trial that will be conducted in the department of pharmacology, BSMMU in collaboration with the department of psychiatry, BSMMU, and Combined Military Hospital (CMH), Dhaka from the day of approval by the IRB to January 2022. A total of 56 patients suffering from OCD will be selected according to inclusion and exclusion criteria. The diagnosis of patients suffering from OCD and the selection of drug and dosage would be performed by a senior professor of the psychiatry department. After completing the necessary formalities including informed consent of the patients, the patient would undergo a selected questionnaire Yale-Brown Obsessive Scale (Y-BOCS-10) to assess the severity of the disease. The patients would be randomly allocated into two arms: control and intervention. Patients in the intervention arm would consist of 30 patients who will receive SSRIs plus NAC. NAC was titrated from 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for the remaining 7 weeks. On the other hand, the control arm would consist of 30 patients who will receive SSRIs plus a placebo for 10 weeks. The severity of symptoms will be assessed after 4 weeks and 10 weeks follow-up. The brain glutamate level, ALT, AST, serum creatinine, and ECG will be measured at baseline and after 10 weeks. The regularity of medicine intake will be ensured over the telephone, pill count, and from the patient's compliance sheet. Statistical analysis will be obtained by SPSS (statistical package for social science) version 24. Paire't' test will be done to compare between two means of before and after the intervention. Proportion test 'Z' will be done to compare the proportion between the intervention group and the placebo group. The calculated 'p' value may suggest the level of significance (significant at p<0.05). Ethical consideration: After approval from IRB every eligible patient will be informed about the intervention and the study objectives. Patients will also be informed that they can participate or to withdraw at any time without compromising their medical care. Patient confidentiality will be strictly maintained. Patient's personal data regarding the name, age, sex, and other information will not be disclosed anywhere and will be used only for research purposes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
OCD
Keywords
N-acetylcysteine, OCD, MRS, Glutamate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental
Arm Type
Active Comparator
Arm Description
This arm includes 30 OCD patients receiving SSRIs
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
This arm includes 30 OCD patients receiving SSRIs
Intervention Type
Drug
Intervention Name(s)
N-acetylcysteine tablet 600mg
Intervention Description
N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Intervention Type
Drug
Intervention Name(s)
Placebo tablet 600mg
Intervention Description
Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Primary Outcome Measure Information:
Title
OCD severity score assessment
Description
Assess the severity score of OCD symptoms by YBOCS-10 at baseline, after 4 weeks, and after10 weeks. And compare the score between two groups. YBOCS-10 range from 0-40 with the following scores: 0-14 Non significant to mild, 15-23 Mild to moderate, 23-29 Moderate to severe, 30-40 Severe to disabling.
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Neurochemical assessment
Description
To estimate the brain glutamate level by Magnetic Resonance Spectroscopy (MRS) at baseline and after 10 weeks supplementation of n-acetylcysteine and SSRI. To compare the brain glutamate level by Magnetic Resonance Spectroscopy (MRS) at baseline and after 10 weeks supplementation of n-acetylcysteine and SSRI.
Time Frame
10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosed OCD patients diagnosed by Psychiatric Consultant of the Department of Psychiatry according to DSM-5 criteria (Appendix VI). Moderate to severe OCD patients having AY-BOCS score > 16 Age: 18 years or above Sex: Both male and female Exclusion Criteria: Patients receiving antidepressant within last two months. Patients having any history of psychiatric and medical conditions will be excluded from the study. Patients having suicidal thoughts. Pregnancy and lactation. Patients who are receiving psychotherapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sadia Binte Anwar Sonia, MBBS
Phone
01752093329
Email
sadiasonia365@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Prof Md. Sayedur Rahman, MBBS,M.Phil
Phone
01971840757
Email
srkhasru@bsmmu.edu.bd
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prof Md. Sayedur Rahman, MBBS, M.Phil
Organizational Affiliation
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Official's Role
Study Chair
Facility Information:
Facility Name
BSMMU
City
Dhaka
ZIP/Postal Code
1000
Country
Bangladesh
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sadia Binte Anwar Sonia, MBBS
Phone
01752093329
Email
sadiasonia365@gmail.com
First Name & Middle Initial & Last Name & Degree
Prof Md. Sayedur Rahman, MBBS,M.Phil
Phone
01971840757
Email
srkhasru@bsmmu.edu.bd
Facility Name
Sadia Binte Anwar Sonia
City
Dhaka
ZIP/Postal Code
1000
Country
Bangladesh
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sadia Binte Anwar Sonia, MBBS
Phone
01752093329
Email
sadiasonia365@gmail.com
First Name & Middle Initial & Last Name & Degree
Prof Md. Sayedur Rahman, MBBS.Mphil
Phone
01971840757
Email
srkhasru@bsmmu.edu.bd

12. IPD Sharing Statement

Learn more about this trial

Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients

We'll reach out to this number within 24 hrs